Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Adicet Bio, Inc. (ACET : NSDQ)
 
 • Company Description   
Adicet Bio Inc. is a biotechnology company. It engages in discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet Bio Inc., formerly known as RESTORBIO INC, is based in Calif.

Number of Employees: 102

 
 • Price / Volume Information   
Yesterday's Closing Price: $12.90 Daily Weekly Monthly
20 Day Moving Average: 484,616 shares
Shares Outstanding: 40.00 (millions)
Market Capitalization: $516.06 (millions)
Beta: 2.59
52 Week High: $21.17
52 Week Low: $6.25
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -18.87% -11.10%
12 Week -5.29% 2.77%
Year To Date -26.24% -12.29%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
500 BOYLSTON STREET 13TH FLOOR
-
BOSTON,MA 02116
USA
ph: 857-315-5528
fax: -
abowdidge@adicetbio.com http://www.adicetbio.com
 
 • General Corporate Information   
Officers
Chen Schor - President; Chief Executive Officer and Director
Nick Harvey - Chief Financial Officer
Jeffrey Chodakewitz - Director
Steve Dubin - Director
Carl L. Gordon - Director

Peer Information
Adicet Bio, Inc. (CORR.)
Adicet Bio, Inc. (RSPI)
Adicet Bio, Inc. (CGXP)
Adicet Bio, Inc. (BGEN)
Adicet Bio, Inc. (GTBP)
Adicet Bio, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 007002108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 40.00
Most Recent Split Date: 9.00 (0.14:1)
Beta: 2.59
Market Capitalization: $516.06 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.51 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.02 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.66
Price/Cash Flow: -
Price / Sales: 13.33
EPS Growth
vs. Year Ago Period: 112.20%
vs. Previous Quarter: 121.28%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 357.02%
ROE
03/31/22 - -13.61
12/31/21 - -25.18
09/30/21 - -27.86
ROA
03/31/22 - -11.97
12/31/21 - -21.62
09/30/21 - -22.93
Current Ratio
03/31/22 - 27.07
12/31/21 - 17.31
09/30/21 - 9.94
Quick Ratio
03/31/22 - 27.07
12/31/21 - 17.31
09/30/21 - 9.94
Operating Margin
03/31/22 - -93.18
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -93.18
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -93.38
12/31/21 - -638.48
09/30/21 - -572.82
Book Value
03/31/22 - 7.78
12/31/21 - 9.49
09/30/21 - 6.82
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©